Revolution Medicines RAS Leadership at ASCO
Decision brief
Answer first · skim in under a minute
Revolution Medicines showcased its confidence in RAS leadership at ASCO, amidst rising competition. This article explores the implications for the pharma landscape.
Revolution Medicines’ RAS leadership pitch at ASCO 2026 rested on hard Phase 3 numbers: oral daraxonrasib halved median overall survival risk versus chemotherapy in previously treated metastatic pancreatic cancer, giving the company’s RAS(ON) platform a concrete clinical anchor rather than conference rhetoric alone.
Contents10 sections
Key Takeaways
- RASolute 302 (NCT06625320) met all primary and key secondary endpoints for daraxonrasib versus investigator’s-choice chemo in previously treated metastatic PDAC.
- In the RAS G12 cohort, median OS was 13.2 months versus 6.6 months (HR 0.40); median PFS was 7.3 versus 3.5 months (HR 0.45).
- Grade ≥3 treatment-related adverse events were 43.6% on daraxonrasib versus 57.5% on chemotherapy; TRAE discontinuations were 1.2% versus 11.2%.
- The asset remains unapproved; NDA timing and EU assessment will decide whether “RAS leadership” becomes market share.
What data underpinned Revolution Medicines’ RAS claim?
On May 31, 2026, Revolution Medicines announced detailed RASolute 302 ASCO plenary results via GlobeNewswire. Daraxonrasib is an oral RAS(ON) multi-selective inhibitor tested at 300 mg once daily against four standard cytotoxic regimens.
The randomized Phase 3 study enrolled 500 patients with previously treated metastatic PDAC (248 daraxonrasib; 252 chemotherapy). Median follow-up at the February 10, 2026 cutoff was 8.5 months. Primary endpoints focused on PFS and OS in RAS G12 mutant tumors, with ITT analyses as key secondaries.
How large was the survival benefit?
In the RAS G12 population, daraxonrasib reduced the risk of death by 60% (HR 0.40; 95% CI 0.30–0.54; p<0.0001), with median OS 13.2 months versus 6.6 months for chemotherapy. PFS HR was 0.45, with median PFS 7.3 versus 3.5 months. Objective response rates were 33.2% versus 11.8%.
ITT results were nearly identical on OS (HR 0.40; median 13.2 vs 6.7 months). Patient-reported outcomes also favored daraxonrasib on time to pain deterioration (HR 0.51) and global health status/quality of life (HR 0.60).
Where is the trial registered and what comes next?
RASolute 302 is registered as NCT06625320 on ClinicalTrials.gov. The company said it intends to submit the package to global regulators, including FDA under a Commissioner’s National Priority Voucher, and noted FDA authorized an expanded access protocol for eligible patients.
For European strategy teams, the practical question is how EMA review timing aligns with U.S. filing and whether label language will cover RAS-wild-type metastatic PDAC given ITT enrollment of patients without identified RAS mutations.
How should competitors read the “RAS leadership” message?
The ASCO plenary elevates Revolution Medicines beyond early RAS inhibitor narrative. Competitors with allele-specific KRAS G12C or G12D programs must now benchmark second-line PDAC survival against a multi-selective oral agent that doubled median OS versus chemo in a 500-patient global trial.
That does not automatically transfer to NSCLC or colorectal settings where Revolution also runs Phase 3 programs. Portfolio teams should separate PDAC practice-change potential from pan-RAS platform valuation until those readouts land.
What safety trade-offs matter for market access?
- Grade ≥3 TRAEs: 43.6% daraxonrasib vs 57.5% chemotherapy.
- Most common Grade ≥3 TRAEs on daraxonrasib: rash (14%), stomatitis (12%).
- One Grade 5 TRAE of pneumonitis (0.4%) on daraxonrasib; none on chemo.
- Treatment-related discontinuation: 1.2% vs 11.2%—a durability signal payers will notice.
What remains unproven?
RASolute 302 does not prove first-line superiority, combination superiority with chemotherapy or immunotherapy, or OS benefit in every RAS allele subclass beyond the reported G12 and ITT analyses. Approval, price, and guideline placement are unresolved. Claims that Revolution Medicines already “leads the RAS market” commercially are premature without a labeled product.
Related NovaPharma coverage
- Revolution Medicines' Pancreatic Cancer Drug: Practice-Changing Results
- Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
- CHMP Approves New Medicines: Key Decisions and Implications
Frequently Asked Questions
What RAS leadership claim did Revolution Medicines support at ASCO 2026?
At ASCO 2026, Revolution Medicines presented pivotal Phase 3 RASolute 302 results for oral RAS(ON) multi-selective inhibitor daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, reporting a 60% reduction in risk of death versus chemotherapy.
What were the key RASolute 302 survival numbers?
In the RAS G12 population, median overall survival was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy (HR 0.40). Median PFS was 7.3 versus 3.5 months (HR 0.45). The trial enrolled 500 patients (NCT06625320).
Is daraxonrasib approved in the EU or US?
No. Daraxonrasib remains investigational. Revolution Medicines said it intends to submit data to global regulators including FDA under a Commissioner’s National Priority Voucher pathway; approval timing is not established in the ASCO disclosure.
Primary Sources
Revolution Medicines pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
